Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H14ClNO2 |
| Molecular Weight | 251.709 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(O)=O)C1=CC=C(N2CC=CC2)C(Cl)=C1
InChI
InChIKey=PIDSZXPFGCURGN-UHFFFAOYSA-N
InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)
| Molecular Formula | C13H14ClNO2 |
| Molecular Weight | 251.709 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Pirprofen is a non-steroidal anti-inflammatory drug, related structurally to drugs such as ibuprofen, ketoprofen and naproxen. Pirprofen was introduced by Ciba-Geigy in 1982 as a treatment for rheumatic diseases. In 1990 due to adverse effects, including some cases of fatal liver toxicity the manufacturers decided to discontinue marketing it worldwide. Pirprofen proved to be useful in the management of both rheumatoid arthritis and osteoarthritis and as an analgesic. In doses of 600-800 mg/d, pirprofen has been found to be as effective as, but not superior to, aspirin 3.6 g/d in relieving the more common symptoms of rheumatoid arthritis. Pirprofen is as effective as, but not superior to, other available NSAIDs in terms of efficacy, tolerability, and incidence of adverse effects. The recommended dosage in osteoarthritis is 450-600 mg/d.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. | 2009-09 |
|
| The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery. | 2008-10-31 |
|
| A peripatetic pediatrician's journey into pediatric rheumatology: Part II. | 2007-06-21 |
|
| Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. | 2003-07 |
|
| A recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids. | 1994-01 |
|
| Remission of severe rheumatoid arthritis following liver transplantation. | 1993-09 |
|
| [Interstitial nephropathy with nephrotic syndrome induced by pirprofen]. | 1986-11 |
|
| [Hepatitis due to pirprofen; 3 cases, 1 fatality]. | 1986-01-01 |
|
| [Cholestatic and cytolytic hepatitis and acute kidney failure caused by pirprofen]. | 1986 |
|
| Pirprofen-induced fulminant hepatitis. | 1985-07 |
|
| Pirprofen and aspirin in the treatment of rheumatoid arthritis. | 1979-05 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3539573
Published clinical trials indicate that pirprofen 600 to 1200 mg/day as 2 or 3 divided doses is a suitable alternative to usual therapeutic dosages of aspirin, flurbiprofen, ibuprofen, indomethacin, ketoprofen, naproxen, piroxicam and sulindac in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, musculoskeletal disorders and non-articular rheumatism. In patients with acute postsurgical, trauma or cancer pain, single oral or intramuscular doses of pirprofen 200 to 400mg provide equivalent analgesic activity to usual therapeutic doses of aspirin, diflunisal, ketoprofen, noramidopyrine, paracetamol and pentazocine.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/804924
Curator's Comment: Pirprofen, racemic 2-[3-chloro-4(3-pyrrolinyl) phenyl] propionic acid, was evaluated for its ability to inhibit the conversion of arachidonic acid into prostaglandin E2 by sheep seminal vesicle prostaglandin synthase in vitro.
The compound proved to be a potent inhibitor with a Ki value of about 1.2 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:42:50 GMT 2025
by
admin
on
Mon Mar 31 18:42:50 GMT 2025
|
| Record UNII |
T7KN291890
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QM01AE08
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
||
|
WHO-ATC |
M01AE08
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
35935
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
C008924
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
Pirprofen
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
m896
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
2213
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
T7KN291890
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
DTXSID7023489
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
3717
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
31793-07-4
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
250-805-8
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
46801-03-0
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
SUPERSEDED | |||
|
C170327
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
DB13722
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
SUB09940MIG
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL188952
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY | |||
|
100000081700
Created by
admin on Mon Mar 31 18:42:50 GMT 2025 , Edited by admin on Mon Mar 31 18:42:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |